Product Description: IDH-305 is an orally available, mutant-selective and brain-penetrant IDH1 inhibitor that targets IDH1 (R132) mutation. IDH-305 exhibits greater than 200 fold selectivity for mutant IDH1 isoforms vs. WT (IC50= 27 nM (IDH1R132H), 28 nM (IDH1R132C), 6.14 µM (IDH1WT))[1][2].
Applications: Cancer-programmed cell death
Formula: C23H22F4N6O2
References: [1]Cho YS, et al. Discovery and Evaluation of Clinical Candidate IDH305, a Brain Penetrant Mutant IDH1 Inhibitor. ACS Med Chem Lett. 2017 Sep 18;8(10):1116-1121./[2]Courtney D DiNardo, et al. A Phase I Study of IDH305 in Patients with Advanced Malignancies Including Relapsed/Refractory AML and MDS That Harbor IDH1R132 Mutations. Blood, 128(22), 1073.
CAS Number: 1628805-46-8
Molecular Weight: 490.45
Compound Purity: 98.75
Research Area: Cancer
Solubility: DMSO : ≥ 150 mg/mL
Target: Isocitrate Dehydrogenase (IDH)
Deutsch
English
